The a-pyrone antibiotic myxopyronin (Myx) inhibits bacterial RNA polymerase (RNAP). Here, through a combination of genetic, biochemical, and structural approaches, we show that Myx interacts with the RNAP ''switch region''-the hinge that mediates opening and closing of the RNAP active center cleft-to prevent interaction of RNAP with promoter DNA. We define the contacts between Myx and RNAP and the effects of Myx on RNAP conformation and propose that Myx functions by interfering with opening of the RNAP active-center cleft during transcription initiation. We further show that the structurally related a-pyrone antibiotic corallopyronin (Cor) and the structurally unrelated macrocyclic-lactone antibiotic ripostatin (Rip) function analogously to Myx. The RNAP switch region is distant from targets of previously characterized RNAP inhibitors, and, correspondingly, Myx, Cor, and Rip do not exhibit crossresistance with previously characterized RNAP inhibitors. The RNAP switch region is an attractive target for identification of new broad-spectrum antibacterial therapeutic agents.
INTRODUCTION
Bacterial RNA polymerase (RNAP) is a proven target for broadspectrum antibacterial therapy (Darst, 2004; Chopra, 2007) . The suitability of bacterial RNAP as a target for broad-spectrum antibacterial therapy follows from the fact that bacterial RNAP is an essential enzyme (permitting efficacy), the fact that bacterial RNAP subunit sequences are highly conserved (permitting for broad-spectrum activity), and the fact that bacterial RNAP-subunit sequences and eukaryotic RNAP-subunit sequences are not highly conserved (permitting therapeutic selectivity).
The rifamycin antibacterial agents-notably rifampicin, rifapentine, and rifabutin-function by binding to and inhibiting bacterial RNAP (Campbell et al., 2001; Darst, 2004; Chopra, 2007) . The rifamycins bind to a site on bacterial RNAP adjacent to the RNAP active center and prevent extension of RNA beyond a length of 2-3 nt. The rifamycins are of clinical importance in treatment of Gram-positive and Gram-negative bacterial infections, are first-line antituberculosis agents, and are the only antituberculosis agents able to rapidly clear infection and prevent relapse. However, the clinical utility of the rifamycin antibacterial agents is threatened by the existence of bacterial strains resistant to rifamycins. Resistance to rifamycins typically involves substitution of residues in or adjacent to the rifamycinbinding site on bacterial RNAP, i.e., substitutions that directly decrease binding of rifamycins.
In view of the public-health threat posed by rifamycin-resistant and multidrug-resistant bacterial infections, there is an urgent need for new classes of antibacterial agents that (1) target bacterial RNAP (and thus have the same biochemical effects as rifamycins) but that (2) target sites within bacterial RNAP distinct from the rifamycin-binding site (and thus do not show crossresistance with rifamycins) (Darst, 2004; Chopra, 2007) .
Structures have been determined for bacterial RNAP and eukaryotic RNAP II (Zhang et al., 1999; Cramer et al., 2000 Cramer et al., , 2001 Ebright, 2000; Darst, 2001; Cramer, 2002; Young et al., 2002; Murakami and Darst, 2003) . The structures reveal that RNAP, bacterial or eukaryotic, has dimensions of $150 Å 3 $100 Å 3 $100 Å and has a shape reminiscent of a crab claw ( Figure 1A ). The two ''pincers'' of the ''claw'' define the active-center cleft, which has a diameter of $20 Å -a diameter that can accommodate a double-stranded nucleic acid-and which has the activecenter Mg 2+ at its base. The largest subunit (b 0 in bacterial RNAP) makes up one pincer, termed the ''clamp,'' and part of the base of the active-center cleft. The second-largest subunit (b in bacterial RNAP) makes up the other pincer and part of the base of the active-center cleft.
The structures further reveal that the RNAP clamp can exist in a range of distinct conformational states, from a fully open clamp conformation that permits unimpeded entry and exit of DNA (clamp perpendicular to floor of active-center cleft) to a fully closed clamp conformation that prevents entry and exit of DNA (clamp rotated into active-center cleft) ( Figure 1A ; Zhang et al., 1999; Cramer et al., 2000 Cramer et al., , 2001 Ebright, 2000; Darst, 2001; Cramer, 2002; Young et al., 2002; Murakami and Darst, 2003) . The transition between the fully open and fully closed clamp conformations involves a 30 swinging motion of the clamp, with a 30 Å displacement of residues at the distal tip of the clamp ( Figure 1A ). It has been proposed that the clamp must open to permit DNA to enter the active-center cleft during early stages of transcription initiation, and that the clamp must close to retain DNA in the active-center cleft during later stages of transcription initiation and during transcription elongation.
The ''switch region'' is located at the base of the clamp and serves as the hinge on which the clamp swings in clamp opening and clamp closure ( Figure 1B ; Cramer et al., 2001; Gnatt et al., 2001; Cramer, 2002) . The switch region adopts different conformations in open and closed clamp conformational states ( Figure 1B ). Several residues of the switch region make direct contacts with DNA phosphates in the transcription elongation complex (Gnatt et al., 2001; Vassylyev et al., 2007) . It has been proposed that direct contacts between the switch region and DNA phosphates might coordinate, and even might mechanically couple, clamp closure and DNA binding ; Gnatt et al., 2001; Cramer, 2002) . In this work, we show that three antibiotics-the a-pyrone antibiotic myxopyronin (Myx), the a-pyrone antibiotic corallopyronin (Cor), and the macrocyclic-lactone antibiotic ripostatin (Rip)-function by binding to the RNAP switch region and preventing interaction of RNAP with promoter DNA, apparently by preventing opening of the clamp to permit entry of promoter DNA during transcription initiation. The three compounds interact with residues that are conserved in Gram-positive and Gram-negative bacterial RNAP and, accordingly, exhibit broad-spectrum antibacterial activity. The three compounds interact, in part, with residues that are not conserved in eukaryotic RNAP I, RNAP II, and RNAP III and, accordingly, do not exhibit crossinhibition of eukaryotic RNAP. The three compounds interact with residues that are remote from the binding site for rifamycins and from the binding sites for other characterized RNAP inhibitors ( Figure 1A ) and, accordingly, do not exhibit crossresistance with rifamycins or other characterized RNAP inhibitors (Table 1) . Taken together, these properties make the three compounds attractive candidates for development as broad-spectrum antibacterial therapeutic agents and make the switch region an attractive target for identification of new broad-spectrum antibacterial therapeutic agents.
RESULTS

Target of Transcription Inhibition by Myx
Myx Myx is polyketide-derived a-pyrone antibiotic produced by the myxobacterium Myxococcus fulvus Mxf50 ( Figure 1C ; Irschik et al., 1983; Kohl et al., 1983) . The compound inhibits growth of a broad spectrum of Gram-positive and Gram-negative bacterial species, including Mycobacterium tuberculosis, Staphylococcus aureus, Bacillus anthracis, Enterococcus faecium, Enterobacter cloacae, Acinetobacter calcoaceticus, Pseudomonas aeruginosa, and Escherichia coli DH21tolC (minimum inhibitory concentrations [MICs] % 12.5 mg/ml for all; MICs % 1 mg/ml for S. aureus, A. calcoaceticus, and E. coli DH21tolC; Irschik et al., 1983; Kohl et al., 1983; Hu et al., 1998; M. Talaue, N. Connell, J.M., and R.H.E., unpublished data) . The compound is bacteriocidal, as assessed with E. coli DH21f2tolC (J.M. and R.H.E., unpublished data). The compound inhibits bacterial RNAP (IC 50 $1 mM) but does not inhibit eukaryotic RNAP II . The compound exhibits no acute toxicity in mice at concentrations up to 100 mg/kg . Total syntheses of Myx have been reported, and analogs of Myx have been prepared (Hu et al., 1998; Doundoulakis et al., 2004; Lira et al., 2007 (Table S1 ).
In the three-dimensional structure of RNAP, the sites of the Myx r substitutions cluster tightly and are located in the RNAP switch region (Figure 2A 1232, 1255, 1275, 1278, 1279, 1285, 1298, 1315, 1317, 1320, 1322 , and 1325 in and near b conserved region I; Table S3 ; Figure S1B) . In the three-dimensional structure of RNAP, the sites of the Myx r substitutions define a single determinant with dimensions of $20 Å 3 $20 Å 3 $10 Å ( Figure 2B ). The determinant is located in the RNAP switch region and encompasses a significant fraction of the RNAP switch region, including switch 2 and segments of b 0 and b adjacent to switch 2 ( Figure 2B ). We conclude that the RNAP switch region contains an extensive determinant for function of Myx.
All identified Myx r substitutions involve residues that are conserved in bacterial RNAP ( Figure S2 ), consistent with the observation that Myx exhibits broad-spectrum activity against bacterial RNAP. Three identified Myx r substitutions involve residues that are not conserved-and indeed are radically different-in eukaryotic RNAP I, RNAP II, and RNAP III (b residues Figure 2C ). We conclude that the RNAP switch region contains a binding determinant for Myx.
The inferred binding site for Myx is remote from the binding site for rifamycins (Figures 1A and 2B) . Consistent with this, Myx r mutants do not exhibit crossresistance with rifampicin (Table 1) , and rifampicin-resistant mutants do not exhibit crossresistance with Myx (Hu et al., 1998; O'Neill et al., 2000; Talaue, N. Connell, J.M., and R.H.E., unpublished data). The inferred binding site for Myx also is remote from the RNAP active center ( Figure 2B ) and from binding sites for nucleic acids and nucleotides (Ebright, 2000; Darst, 2001; Cramer, 2002; Young et al., 2002; Murakami and Darst, 2003) . Indeed, the inferred binding site for Myx is nearly completely buried within the base of the b 0 pincer ( Figure 2B ). We infer that it is unlikely that Myx functions through direct steric interactions with the 
Biochemical Basis of Transcription Inhibition by Myx
Transcription involves the following reactions (Record et al., 1996; Young et al., 2002; Murakami and Darst, 2003) : (1) RNAP binds to promoter DNA to yield an RNAP-promoter closed complex (RP c ); (2) RNAP inserts positions À11 to +15 of the promoter DNA into the RNAP active-center cleft to yield an RNAP-promoter intermediate complex (RP i ); (3) RNAP unwinds positions À11 to +2 of promoter DNA to yield an RNAP-promoter open complex (RP o ); (4) RNAP enters into initial synthesis of RNA, engaging in cycles of synthesis and release of short RNA products (abortive RNA products), as an RNAP-promoter initial transcribing complex (RP itc ); and (5) upon synthesis of an RNA product of a critical threshold length of $9-11 nt, RNAP breaks its interactions with promoter DNA and enters into processive synthesis of RNA as an RNAP-DNA elongation complex (RD e ).
Myx Inhibits Transcription Initiation
As a first step to determine the biochemical basis of transcription inhibition by Myx, we performed run-off transcription experiments (methods as in Mukhopadhyay et al., 2004) . The results indicate that Myx inhibits the formation of both abortive RNA products (products of transcription initiation; 3 nt and 4 nt species produced in large stoichiometric excess over the DNA template) and fulllength RNA products (products of transcription initiation followed by transcription elongation; species produced in stoichiometric equivalence with the DNA template) (Figures 3A and S3A) . Within experimental error, the median effective concentrations, IC 50 s, for inhibition of formation of abortive products and full-length products are identical to each other (1.7 ± 0.6 mM versus 1.3 ± 0.3 mM; Figure 3A ) and are identical to the equilibrium dissociation constant, K d , for RNAP-Myx interaction (0.6 ± 0.3 mM; Figure 2C ). The inhibition is specific and requires the RNAP switch region; a Myx r substitution in the RNAP switch region abrogates inhibition (Figures 3A and S3B) . The inhibition exhibits a profound order-of-addition dependence; inhibition is observed only when interaction of RNAP with Myx is allowed to precede interaction of RNAP with promoter DNA ( Figures 3A and S3C ). Fluorescence-detected abortive initiation assays confirm that Myx inhibits formation of abortive products, confirm that inhibition is switch-region dependent, and confirm that inhibition is order-of-addition dependent ( Figure S4 ). The observation that Myx inhibits formation of abortive products indicates that Myx inhibits transcription initiation or inhibits both transcription initiation and transcription elongation. The observation that inhibition requires interaction of RNAP with Myx prior to interaction of RNAP with promoter DNA suggests that Myx inhibits transcription initiation and does not (or at least does not effectively) inhibit transcription elongation. Myx Inhibits Interaction of RNAP with Promoter DNA To determine whether Myx inhibits steps in transcription initiation up to and including formation of a stable, heparin-resistant RNAPpromoter open complex, we performed fluorescence-detected electrophoretic mobility-shift experiments (methods as in Mukhopadhyay et al., 2004) . The results indicate that Myx inhibits formation of a stable, heparin-resistant RNAP-promoter open complex ( Figures 3B and S5) . Within experimental error, the IC 50 for the inhibition (0.8 ± 0.3 mM; Figures 3B and S5 ) is identical to the IC 50 for inhibition of transcription and the K d for RNAP-Myx interaction (1.3 ± 0.3 mM and 0.6 ± 0.3 mM; Figures 2C and 3A) . The inhibition is specific and requires the RNAP switch region; a Myx r substitution in the RNAP switch region abrogates inhibition (Figures 3B and S5) . The inhibition exhibits the same profound order-of-addition dependence as observed for inhibition of transcription; the inhibition is observed only when interaction of RNAP with Myx is allowed to precede interaction of RNAP with promoter DNA (Figures 3B and S5) . Equivalent results are obtained with all promoters tested, including consensus À35/À10 promoters, nonconsensus À35/À10 promoters, and extended À10 promoters ( Figures 3B and S5) . We conclude that Myx functions by preventing interaction of RNAP with promoter DNA to form a stable, heparin-resistant RNAP-promoter open complex, preventing DNA binding, DNA retention, or both. We note that this conclusion is consistent with the proposal above that Myx functions by interfering with opening and/or closing of the RNAP clamp-preventing clamp opening required for DNA binding and/or preventing clamp closing required for DNA retention. Myx Inhibits Interaction of RNAP with Promoter Positions À11 to +15 To map the RNAP-promoter interaction inhibited by Myx, we performed fluorescence-detected electrophoretic mobility-shift experiments with promoter subfragments. The results indicate that inhibition does not occur with promoter subfragments that lack promoter positions À11 to +15 ( Figures 3C and S6 ). Thus Myx does not inhibit formation of a stable, heparin-resistant complex of RNAP with a DNA fragment that lacks positions À11 to +15 of the template strand and positions À6 to +15 of the nontemplate strand (''fork-junction'' DNA fragment; Guo and Gralla, 1998; Murakami et al., 2002b) (Figures 3C and  S6) . Equivalent results are obtained with fork-junction DNA fragments having sequences of other promoters and with fork-junction DNA fragments having different-length nontemplate-strand overhangs ( Figures 3C and S6 ). We infer that Myx interferes with interactions of RNAP with the promoter DNA segment comprising positions À11 to +15. We note that positions À11 to +15 correspond, precisely, to the positions that are proposed to bind within the RNAP active-center cleft, and to be affected by opening and closing of the RNAP clamp, in structural models of transcription-initiation complexes (Naryshkin et al., 2000; Ebright, 2000; Young et al., 2002; Murakami and Darst, 2003) . We suggest that Myx functions by interfering with opening and/or closing of the RNAP clamp, preventing clamp opening required for entry of promoter positions À11 to +15 and/or preventing clamp closing required for retention of promoter positions À11 to +15.
Myx Inhibits Interaction of RNAP with Promoter
Positions À11 to +15 in Double-Stranded Form The promoter DNA segment comprising positions À11 to +15 contains the region that is unwound during transcription initiation to form the ''transcription bubble'' (positions À11 to +2; Record et al., 1996; Young et al., 2002; Murakami and Darst, 2003) . To determine whether the RNAP-promoter interaction inhibited by Myx involves the transcription-bubble region in double-stranded form, in single-stranded DNA form, or both, we performed fluorescence-detected electrophoretic mobility-shift experiments with promoter derivatives in which the transcription-bubble region was constrained to be in single-stranded form. The results indicate that inhibition does not occur if the transcription-bubble region is constrained to be in single-stranded form ( Figures 3D-3F and S7). Thus Myx does not inhibit formation of stable, heparin-resistant complexes of RNAP with DNA fragments in which positions À11 to +2 are maintained in single-stranded form by the presence of noncomplementary template-and nontemplate-strand sequences (''artificial-bubble'' DNA fragment; Tripatara and deHaseth, 1993; Helmann and deHaseth, 1999) , by the presence of a template-strand gap (''template-strand-gap'' DNA fragment), or by the presence of a nontemplate-strand gap (''nontemplate-strand-gap'' DNA fragment) (Figures 3D-3F ). Myx also does not inhibit formation of stable, heparin-resistant complexes of RNAP with an oligonucleotide comprising positions À21 to +15 of the nontemplate strand (''nontemplatestrand oligonucleotide''; Marr and Roberts, 1997) ( Figure S7 ). Equivalent results are obtained in experiments using RNAP and DNA concentrations that are one-tenth those in the experiments in Figure 3 and that are unequivocally subsaturating, ruling out the possibility that inhibition occurs but is masked by a high affinity of RNAP for DNA fragments in which positions À11 to +2 are in single-stranded form ( Figure S8 ). Further results indicate that Myx has no effect on equilibrium dissociation constants for RNAP-DNA interaction, K d,RNAP-DNA , for DNA fragments in which positions À11 to +2 are in single-stranded form ( Figure S9 ). We infer that Myx interferes with interactions of RNAP with the promoter DNA when, and only when, the transcription-bubble region is in double-stranded form. We note that the transcription-bubble region interacts with RNAP in double-stranded form in early stages of transcription initiation, before and during entry of DNA into the RNAP active-center cleft (in RP c and RP i ), but interacts with RNAP in single-stranded form in late stages of transcription initiation, after entry of DNA into the RNAP active-center cleft (in RP o and RP itc ; Record et al., 1996; Young et al., 2002; Murakami and Darst, 2003) . We propose that Myx functions in early stages of transcription initiation, before or during entry of DNA into the RNAP active-center cleft (in RP c or RP i ). We note further that structures of RNAP suggest that opening of the RNAP clamp is required for entry of double-stranded DNA (diameter $20 Å ) into the RNAP active-center cleft but not for entry of singlestranded DNA (diameter $7 Å ) into the RNAP active-center cleft (see Murakami et al., 2002a; Vassylyev et al., 2002) . We propose that Myx functions by interfering with opening of the RNAP clamp in early stages of transcription initiation-preventing clamp opening required for entry of promoter positions À11 to +15, in doublestranded form, into the RNAP active-center cleft in early stages of transcription initiation.
According to this proposal, Myx inhibits formation of stable, heparin-resistant complexes of RNAP with DNA fragments that contain promoter positions À11 to +15 in double-stranded form by preventing clamp opening and blocking entry of double-stranded DNA into the RNAP active-center cleft, thereby blocking establishment of RNAP-DNA interactions essential for heparin resistance (interactions that minimally involve positions À11 to À7 of one DNA strand; Guo and Gralla, 1998; Helmann and deHaseth, 1999) . According to this proposal, Myx does not inhibit formation of stable, heparin-resistant complexes of RNAP with DNA fragments that contain the corresponding positions in single-stranded form since prevention of clamp opening does not block entry of single-stranded DNA into the RNAP active-center cleft.
The artificial-bubble DNA fragment of Figure 3D is able to serve as a template for transcription (Tripatara and deHaseth, 1993; Helmann and deHaseth, 1999) . Myx does not efficiently inhibit transcription from the artificial-bubble DNA fragment at concentrations at which it efficiently inhibits transcription from promoter DNA fragments ( Figure S10 ). A DNA fragment having a 3 0 -terminal single-stranded overhang also is able to serve as a template for transcription (''tailed template''; Kadesch and Chamberlin, 1982) . Myx does not efficiently inhibit transcription from a tailed template at concentrations at which it efficiently inhibits transcription from promoter DNA fragments ( Figure S11) . A single-stranded closed-circular DNA construct also is able to serve as a template for transcription (''rolling-circle-transcription template''; Daubendiek and Kool, 1997). Myx does not efficiently inhibit transcription from the rolling-circle-transcription template at concentrations at which it efficiently inhibits transcription from promoter DNA fragments ( Figure S12 ). We infer that Myx, in the relevant concentration range, does not efficiently inhibit steps in transcription subsequent to interaction of RNAP with promoter positions À11 to +15 in double-stranded form (the step bypassed by use of artificial-bubble, tailed, and rolling-circle-transcription templates).
Structural Basis of Transcription Inhibition by Myx
We have determined a crystal structure of Thermus thermophilus RNAP holoenzyme in complex with Myx. (Myx inhibits T. thermophilus RNAP holoenzyme with IC 50 = 20 mM [J.M. and R.H.E., unpublished data].) Crystals of RNAP-Myx were obtained by soaking pre-existing crystals of RNAP in solutions containing Myx, X-ray diffraction data were collected at the Brookhaven National Light Source beamline X-25, and the structure was solved by molecular replacement and refined to a resolution of 3.0 Å (96% complete), an R work of = 0.235, and an R free of 0.289 (Table 2 ; Figures S13 and S14). The structure defines the location of the binding site for Myx, defines contacts between Myx and RNAP, and defines effects of Myx on RNAP conformation.
Myx Interacts with the RNAP Switch Region
Myx binds within the RNAP switch region, consistent with the genetic data above ( Figure 4A ). Myx makes direct interactions with switch 1 and, especially, switch 2 (b 0 residues 1319-1328 and 330-347) and also makes direct interactions with adjacent segments of the b 0 and b subunits (b 0 residues 1346-1357 and b residues 1270-1292 and 1318-1328) ( Figure 4B ). (Here and elsewhere in the text, to facilitate comparison of structural data to genetic and biochemical data obtained with E. coli RNAP, residues are numbered as in E. coli RNAP. In the figures, residues are numbered, in parallel, as in T. thermophilus RNAP and as in E. coli RNAP.) The interactions with switch 1 and switch 2 involve residues conserved both in bacterial RNAP and in eukaryotic RNAP I, RNAP II, and RNAP III; the interactions with adjacent segments of b 0 and b involve residues conserved in bacterial RNAP but not conserved in eukaryotic RNAP I, RNAP II, or RNAP III, consistent with the selectivity of Myx. Myx contacts, or is within 5 Å of, all residues at which substitutions conferring high-level (R16-fold) Myx resistance are obtained ( Figure 4B ).
Myx does not overlap the RNAP active-center cleft or the predicted positions of nucleic acids in transcription initiation and elongation complexes ( Figure 4A ). Indeed, Myx is nearly completely buried, with little surface accessibility on the interior of the RNAP active-center cleft and with no surface accessibility on the exterior of RNAP. These observations support the inference from genetic data above that that Myx must inhibit transcription through allosteric interactions, not through direct, steric interactions. Myx Interacts with a Nearly Completely Enclosed, Primarily Hydrophobic, Binding Pocket in the RNAP Switch Region Myx interacts with a nearly completely enclosed, primarily hydrophobic, binding pocket ( Figure 5 ). The binding pocket is crescent 
where F o and F c are observed and calculated structure factors, respectively. The crystals have the symmetry of space group P3 2 with perfect (50%) hemihedral twinning and twinning operator (-h,-k,l), leading to apparent hexagonal (P6/m) intensity symmetry. Processing and scaling were carried out in P6 5 followed by expansion to P3 2 for structure solution and refinement.
shaped, has dimensions of $25 Å (measured along the curve of the crescent) 3 $5 Å 3 $4 Å , and has a volume of $500 Å 3 (Figures 5A and 5C) . The binding pocket connects to an adjacent hydrophobic pocket having a volume of $120 Å 3 ( Figures 5A and  5C ). The adjacent hydrophobic pocket is located close to the terminus of the Myx dienone side chain and, as such, potentially is able to accommodate the one-carbon side-chain extension present in myxopyronin B (see Irschik et al., 1983; Kohl et al., 1983) and the seven-carbon side-chain extension present in Cor (see Irschik et al., 1985; Jansen et al., 1985 ; see section on Cor, below). The divider between the binding pocket and the adjacent hydrophobic pocket is formed by the side chain of bLeu1326 (see section on Cor, below). The binding pocket connects to the RNAP active-center cleft through an opening with dimensions of $5 Å 3 $4 Å ( Figures 5A and 5C ). The opening is located close to the C16-C17 methyl and the C15 carbonyl of the Myx dienone side chain and to the C4 hydroxyl of the Myx a-pyrone ring. We propose that Myx accesses the binding pocket by entering the RNAP active-center cleft and threading through this opening.
Contacts between residues of RNAP and Myx are shown in Figure 5B and are summarized in Figure 5C . A network of H-bonds centered on an ordered bound water molecule engages the nitrogen atom and both oxygen atoms of the enecarbamate moiety of Myx. The network involves the ordered bound water molecule (which yields unequivocal electron density; Figure S14 ), the side-chain ammonium of b 0 Lys1348, the side-chain carboxyl of b 0 Asp802, and the side-chain indole NH of bTrp1276. The side-chain carboxyl of bGlu1279 forms an H-bond with the carbonyl oxygen of the enecarbamate moiety Four substitutions conferring high-level (R16-fold) resistance to Myx are predicted to disrupt RNAP-Myx H-bonds (b1279Glu/Gly, b1279Glu/Lys, bSer1322/Pro, and bSer1322/Val), and at least one of these is predicted also to introduce steric conflict with Myx (b1279Glu/Lys). Five substitutions conferring high-level resistance to Myx are predicted to disrupt favorable RNAP-Myx van der Waals interactions and to introduce steric clash with Myx (b 0 345Lys/Arg, b 0 345Lys/Asn, b 0 345Lys/Thr, b1275 Val/Met, and b1275Val/Phe). The remaining substitution conferring highlevel resistance to Myx is predicted to introduce steric conflict with Myx (b 0 1351Val/Phe). With one exception, the structure is consistent with, and can account for, published structure-activity relationships for synthetic Myx analogs (Doundoulakis et al., 2004; Lira et al., 2007) . The one exception involves O-methylation of the C4 hydroxyl of the a-pyrone ring of Myx, which the structure predicts would disrupt an intramolecular H-bond important for establishing the orientation of the dienone side chain relative to the a-pyrone ring, would disrupt a potential intermolecular H-bond, and would introduce steric clash ( Figures 5B and 5C and text above), but which the published work indicates does not have large effects on RNAP-Myx interaction (Lira et al., 2007) . Resynthesis and retesting of the O-methyl analog indicates that the published work is incorrect, and that O-methylation in fact profoundly impairs RNAP-Myx interaction (A. Wasmuth, Y. Sun, C. Self, G. Olson, J.M., and R.H.E., unpublished data).
The structure suggests opportunities for preparation of optimized Myx analogs, including (1) appending functionality at C24, potentially enabling formation of interactions with residues at and in the adjacent hydrophobic pocket; (2) appending functionality at C17, potentially enabling formation of interactions with residues at and in the RNAP active-center-cleft; (3) replacing the enecarbamate carbonyl oxygen by an H-bond donor, potentially enabling formation of an H-bond with bGlu1279 without the requirement for (presumably unfavorable) tautomerization of the enecarbamate or (presumably unfavorable) protonation of bGlu1279; and (4) appending a hydroxyl or analogous group at the position of the enecarbamate nitrogen, potentially enabling formation of an H-bond network with b 0 Lys1348, b 0 Asp802, and bTrp1276 without the requirement for (presumably unfavorable) recruitment and immobilization of a water molecule. Myx Interacts with an RNAP Conformational State in which the RNAP Clamp and RNAP Switch Region Are in a Partly Closed, or Partly Closed to Fully Closed, Conformation The RNAP clamp in the crystal structure of RNAP-Myx adopts the same clamp conformation as in the crystal structure of unliganded RNAP in the same crystal form: i.e., a partly closed clamp conformation ( Figures 4A, S13A , and S13B; see Vassylyev et al., 2002) . This observation permits the conclusion that binding of Myx is compatible with a partly closed clamp conformation. However, this observation does not permit the conclusion that binding of Myx favors, stabilizes, or induces an intermediate clamp conformation since clamp conformation in this crystal form is constrained by, and may be determined by, crystal-lattice interactions (crystal-lattice interactions with the clamp, with a b 0 nonconserved domain appended to the clamp, and with a s domain associated with the clamp).
The RNAP switch region in the crystal structure of RNAP-Myx adopts a different conformation from that in the crystal structure of unliganded RNAP in the same crystal form ( Figure S15) . The difference in conformation involves a nine-residue segment of switch 2-a nine-residue segment that differs in conformation in open, partly closed, and fully closed clamp conformational states (b 0 residues 336-344; Figure 1B) . The difference in conformation involves 1-4 Å displacements of Ca atoms of the nineresidue segment toward positions intermediate between those in partly closed and fully closed clamp conformational states ( Figures S15 and 1B) . The nine-residue segment contains a residue that contacts template-strand DNA in transcription complexes (b 0 residue 339; see Gnatt et al., 2001; Vassylyev et al., 2007) ; however, since Myx does not efficiently inhibit interaction between RNAP and template-strand DNA in relevant concentration ranges ( Figures 3D, 3F and S10-S12), possible differences in interaction between the nine-residue segment and templatestrand DNA cannot, in of themselves, account for transcription inhibition by Myx.
Target and Mechanism of Transcription Inhibition by Cor
Cor is a polyketide-derived a-pyrone antibiotic structurally related to Myx ( Figure 1C ; Irschik et al., 1985; Jansen et al., 1985) . Cor is produced by the myxobacterium Corallococcus coralloides Cc c127 Jansen et al., 1985) . The compound inhibits growth of a broad spectrum of Grampositive and Gram-negative bacterial species, including M. tuberculosis, S. aureus, S. pneumoniae, B. anthracis, and E. coli DH21tolC (MICs % 12.5 mg/ml for all; MIC % 0.1 mg/ml for S. aureus; Irschik et al., 1985; M. Talaue, N. Connell, J.M., and R.H.E., unpublished data) . The compound is bacteriocidal, as assessed in experiments with E. coli DH21f2tolC (J.M. and R.H.E., unpublished data) . The compound inhibits bacterial RNAP (IC 50 $4 mM) but does not inhibit eukaryotic RNAP II .
Cor differs from Myx only by possession of a seven-carbon extension of the dienone side chain ( Figure 1C ). Perhaps unsurprisingly, in view of the structural similarity between Myx and Cor, analysis of crossresistance patterns indicates that all mutants that exhibit high-level (R16-fold) resistance to Myx also exhibit resistance to Cor (Table 1) . We infer that Cor interacts with a target that overlaps the target for Myx. To define further the target for Cor, we performed saturation mutagenesis-targeting codons for RNAP residues located within 30 Å of sites of Myx-resistant, Cor-crossresistant mutants-and we isolated and characterized more than 75 additional Cor-resistant mutants (Table  S4 ; Figure S16 ). With one exception, all identified substitutions that confer high-level (R8-fold) resistance to Cor also confer resistance to Myx (Table 1) . We conclude that Cor interacts with the same target as Myx.
The one exception, a substitution that confers high-level resistance to Cor but that does not confer resistance to Myx, involves b residue 1326 (b1326Leu/Trp; Table 1 ). We infer that b residue 1326 interacts with the seven-carbon side-chain extension present in Cor but not in Myx. Consistent with this inference, in the three-dimensional structure of the RNAP-Myx complex, b1326 is located close to the ligand dienone side-chain terminus, the point of attachment of the seven-carbon side-chain extension present in Cor (Figures 5A-5C ). Further consistent with this inference, in the three-dimensional structure of the RNAP-Myx complex, b1326 forms one wall of an adjacent hydrophobic pocket that would have sufficient volume to accommodate the seven-carbon side-chain extension present in Cor if b1326 is Leu (as in the wild-type enzyme) but not if b1326 is Trp (as in the mutant enzyme) (Figures 5A and 5C) .
Experiments addressing the biochemical basis of transcription inhibition by Cor indicate that Cor inhibits transcription initiation, prevents interaction of RNAP with promoter DNA, prevents interaction with promoter positions À11 to +15, and prevents interaction with promoter positions À11 to +15 when, and only when, these positions are in double-stranded form (Figures S17 and S18). We conclude that Cor shares the same target and same mechanism as Myx.
Target and Mechanism of Transcription Inhibition by Rip
Rip is a polyketide-derived macrocylic-lactone antibiotic structurally unrelated to Myx and Cor ( Figure 1C ; Irschik et al., 1995; Augustiniak et al., 1996) . Rip is produced by the myxobacterium Sorangium cellulosum So ce377 (Irschik et al., 1995; Augustiniak et al., 1996) . The compound inhibits growth of S. aureus and E. coli DH21tolC (MICs % 1 mg/ml; Irschik et al., 1995; J.M. and R.H.E., unpublished data) . The compound is bacteriocidal, as assessed in experiments with E. coli DH21f2tolC (J.M. and R.H.E., unpublished data). The compound inhibits bacterial RNAP (IC 50 $0.8 mM) but does not inhibit eukaryotic RNAP II (Irschik et al., 1995) .
Rip exhibits no structural similarity to Myx and Cor, apart from a general similarity in size and hydrophobic character ( Figure 1C) . Surprisingly, in view of the lack of structural similarity, analysis of crossresistance patterns indicates that all identified mutants that exhibit high-level resistance to Myx and Cor also exhibit resistance to Rip (Table 1) . We infer that Rip interacts with a target that overlaps the target for Myx and Cor. To define further the target for Rip, we performed saturation mutagenesis-targeting codons for RNAP residues located within 30 Å of sites of Myx-resistant, Rip-crossresistant mutants-and we isolated and characterized 50 additional Rip-resistant mutants (Table S5 ; Figure S19 ). With one exception (b1326Leu/Trp; see preceding section), all identified substitutions conferring high-level resistance to Rip also confer resistance to Myx (Table 1) . Without exception, all identified substitutions conferring high-level resistance to Rip also confer resistance to Cor (Table 1) . We conclude that Rip interacts with the same target as Myx and Cor.
Experiments addressing the biochemical basis of transcription inhibition by Rip indicate that Rip inhibits transcription initiation, prevents interaction of RNAP with promoter DNA, prevents interaction with promoter positions À11 to +15, and prevents interaction with promoter positions À11 to +15 when, and only when, these positions are in double-stranded form ( Figures S20 and  S21) . We conclude that Rip, despite its lack of structural similarity to Myx and Cor, shares the same target and mechanism as Myx and Cor. We conclude, thus, that at least two different chemotypes, the a-pyrone chemotype and the macrocyclic-lactone chemotype, function through this target and mechanism.
DISCUSSION
Our genetic results establish that Myx interacts with the RNAP switch region (Figures 2, S1 , and S2): i.e., with the hinge that mediates rotation of the RNAP clamp relative to the remainder of RNAP and, thus, that mediates opening and closing of the RNAP active-center cleft ( Figures 1A and 1B) . Our biochemical results establish that Myx inhibits interactions of RNAP with promoter DNA, establish that Myx inhibits interactions with the promoter DNA segment that enters the RNAP active-center cleft during transcription initiation (i.e., promoter positions À11 to +15), and establish that Myx inhibits interactions with this promoter DNA segment when it is in a double-stranded state (i.e., the state present before and during entry of promoter DNA into the RNAP active-center cleft, during early stages of transcription initiation) but not when it is present in a single-stranded state (i.e., the state present after entry of promoter DNA into the RNAP active-center cleft, during late stages of transcription initiation) (Figures 3 and S3-S12). Our structural results define contacts between Myx and RNAP and indicate that Myx interacts with an RNAP conformational state in which the RNAP clamp and RNAP switch region are in a partly closed, or partly closed to fully closed, conformation (Figures 4, 5 , and S13-S15). Based on these results, we propose that Myx inhibits transcription by locking the RNAP switch region in one conformation and thereby locking the RNAP clamp in one conformation-a partly closed, or partly closed to fully closed, conformation-thereby preventing opening of the RNAP active-center cleft to permit entry of double-stranded DNA during transcription initiation. According to this proposal, Myx functions essentially by ''hinge jamming.'' Our results further indicate that two other antibiotics, the structurally related a-pyrone antibiotic Cor and the structurally unrelated macrocyclic-lactone antibiotic Rip, share the same target as Myx and the same mechanism as Myx (Table 1; Figures  S16-S21) .
The results define a target and a mechanism for inhibition of RNAP. The results, further, provide experimental evidence for functional significance of the RNAP switch region, experimental evidence for functional significance of opening and closing of the RNAP clamp, and experimental evidence supporting the hypothesis that the RNAP clamp must open to permit DNA to enter the RNAP active-center cleft during transcription initiation. As such, the results have implications for understanding mechanisms of transcription and mechanisms of transcriptional regulation.
Based on several considerations, we suggest that the RNAP switch region is an exceptionally attractive target for discovery of new broad-spectrum antibacterial therapeutic agents. First, the switch region comprises residues that are highly conserved in both Gram-positive bacterial RNAP and Gram-negative bacterial RNAP ( Figure S2 )-providing a basis for broad-spectrum activity of compounds that function through the switch region. Second, the switch region contains residues that are not conserved, and indeed are radically different, in human RNAP I, RNAP II, and RNAP III ( Figure S2 )-providing a basis for therapeutic selectivity of compounds that function through the switch region. Third, the switch region is distant from the binding site for rifamycins ( Figure 1A ) and from the binding sites for other characterized inhibitors of bacterial RNAP (see Darst, 2004; Chopra, 2007) , providing a basis for absence of crossresistance with rifamycins (Table 1 ) and for absence of crossresistance with other characterized inhibitors of bacterial RNAP (unpublished data). Fourth, the ligand binding site in the switch region comprises a nearly completely enclosed, predominantly hydrophobic, pocket ( Figures 5A and 5C ), providing a basis for efficient ''druggability'' by multiple chemotypes (Table 1; Figures 1C, 2 , S16, and S19), facilitating in silico rational design of optimized ligands, and facilitating in silico virtual screening for new ligands.
We point out that the mechanistic role of the RNAP switch region (hinge for movement of domains) and the structural character of the ligand binding site in the RNAP switch region (nearly completely enclosed, predominantly hydrophobic, pocket) are reminiscent of the mechanistic role and structural character of the HIV-1 reverse transcriptase NNRTI site (nonnucleoside reverse-transcriptase inhibitor site; Kohlstaedt et al., 1992; Tantillo et al., 1994; Sluis-Cremer et al., 2004) . The HIV-1 reverse transcriptase NNRTI site is druggable by multiple chemotypes and is the target for multiple antiviral agents in current clinical use. We suggest that the RNAP switch region may exhibit similarly high druggability and similarly high utility.
Priorities for basic research include determination of structures of complexes of RNAP with Cor and Rip (to define interactions with the seven-carbon-atom side-chain extension in Cor and to define interactions with the macrocyclic-lactone chemotype of Rip) and determination of effects of switch-region-target inhibitors on RNAP clamp conformation and dynamics in solution (addressable by use of fluorescence resonance energy transfer; A. Chakraborty, Y. Korlann, D. Wang, S. Weiss, and R.H.E., unpublished data). Priorities for applied research include cloning and surrogate-host expression of biosynthetic genes for Myx, Cor, and Rip (to overcome an important obstacle to possible clinical application of Myx, Cor, and Rip-namely, the relatively poor fermentation characteristics of the myxobacterial strains that produce these compounds), in silico rational design of optimized switch-region-target inhibitors, and in silico virtual screening and in vitro target-directed high-throughput screening for new switch-region-target inhibitors.
EXPERIMENTAL PROCEDURES
Full details of Experimental Procedures are presented in the Supplemental Data.
Mutagenesis
Random mutagenesis was performed by use of PCR amplification, exploiting the baseline error rate of PCR amplification (methods analogous to those in Mukhopadhyay et al., 2004 , but with PCR amplification of entire plasmid molecules using Pfu DNA polymerase). Saturation mutagenesis was performed by use of PCR amplification with ''doped'' primers (methods analogous to those in Mukhopadhyay et al., 2004 , but using pooled sets of ''doped'' primers).
Microbiological Assays
Complementation assays and MIC assays were performed essentially as in Tuske et al. (2005) .
RNAP-Myx Interaction Assays
RNAP-Myx interaction was detected by monitoring quenching by Myx of fluorescence emission of RNAP Trp residues (l ex = 280 nm; l em = 330 nm).
RNAP-DNA Interaction Assays RNAP-DNA interaction assays were performed essentially as in Mukhopadhyay et al. (2004) .
Transcription Assays
Run-off transcription assays and fluorescence-detected abortive initiation assays were performed essentially as in Mukhopadhyay et al. (2004) . Rolling-circle transcription assays were performed using the Kool NC-45 kit (Epicenter, Inc.).
Structure Determination
Crystallization, crystal handling, data collection, structure solution, and refinement were performed by methods analogous to those in Tuske et al. (2005) .
ACCESSION NUMBERS
Atomic coordinates and structure factors for RNAP-Myx have been deposited in the PDB (PDB accession number 3DXJ).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, five tables, and twenty-one figures and can be found with this article online at http://www.cell.com/cgi/content/full/135/2/295/DC1/.
